CEO Update | 13 February 2023

New Department for Science, Innovation and Technology

Prime Minister Rishi Sunak reorganised the UK Government last week creating brand new departments including the Department for Science, Innovation and Technology (DSIT). These changes impact most of the key policy areas the BIA engages with the UK government on and will have broader implications beyond the headlines. Here is my initial take.

For life sciences, it’s the George and Will show

George Freeman proudly announced on Twitter that he and Will Quince are now co-ministers for life science – George in the new DSIT and Will in the Department of Health and Social Care (DHSC). This is great news as both know our organisation and its capabilities well. We congratulate them on the new appointments and look forward to continued strong engagement with them. 

AI and EngBio as well as life sciences called out as priorities at the DSIT’s launch

In the official launch of the DSIT, the five technologies of tomorrow – quantum, AI, engineering biology (EngBio), semiconductors and future telecoms – were called out as priorities along with space, life sciences and green technologies. Now in one single department for the very first time. 
The new Secretary of State Michelle Donelan’s first announcement was to award £40 million of funding to the Rosalind Franklin Institute to help advance vital health research technologies such as spotting early signs of degenerative diseases like Alzheimer's. She visited the Institute in Harwell last Thursday and set out the priorities for DSIT

This brand-new Department has been established to deliver the Prime Minister’s ambition for the UK to become a science and technology superpower and to improve the lives of everyone across the country through stronger growth, better jobs and bold discoveries. This move demonstrates the seriousness with which government takes the science agenda, following Sunak’s pledge to boost this high-growth sector and make the UK a science superpower. 

Goodbye DIT and BEIS, hello Energy and DBiT

The other key change was the restructuring of and merger between the Department for Business, Energy and Industrial Strategy (BEIS) and the Department of Trade (DIT) into the new Department for Business and Trade (DBT) with Kemi Badenoch MP becoming its Secretary of State. A new separate Department of Energy Security and Net Zero has been formed with Grant Shapps moving to head this up. 

With several core functions within these departments' remit, it will take some time for this reorganization to shake down and it remains to be seen how key civil service resources will be divided between the new departments, with the Office for Life Sciences likely bridging split the DHSC and DSIT but the engagement with DBT not yet clear. 

We will continue to update BIA members as we build relationships with new ministers and strengthen those with pre-existing ones. If you would like more detail on who is who, read BIA’s updated Guide to the Government. If you would like us to provide a webinar to discuss this please email me – should we get 20 'yes', we’ll set one up.

Ahead of the Budget – thanks to those who provided info on R&D tax credits

Our work ahead of the Budget continues, focused on making a case for R&D tax credits for knowledge-intensive companies. The survey data members provided last week has been key. It is also interesting to see the debate about the future focus of fiscal policy spill over from discussions in the Conservative Party to front-page media campaigning – with life sciences as the exemplar industry. Many many more conversations in Whitehall are to be had in the coming weeks on effective ways to grow the innovative economy.

Pharmaron & Vaccitech plc announce strategic partnership for development and cGMP manufacturing services

We are pleased to hear about the partnership announcement between Pharmaron and Vaccitech. The partnership is focused on development and cGMP manufacturing services for Vaccitech’s Adenoviral Vector programme, where Pharmaron will be a key part of Vaccitech’s manufacturing network to support novel T cell immunotherapeutics and vaccines from its proprietary ChAdOx1 viral vector platform. 


Steve Bates Headshot.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates

CEO Update | 27 March 2023

The UK Government published last week the long-awaited response to the consultation on proposals to improve the UK clinical trials legislation, with a foreword by life science champions Sir John Bell and Sir Jon Symonds. These reforms represent the biggest overhaul in UK clinical trials regulation in over 20 years and will make the UK one of the best countries to conduct clinical research for the benefit of patients and the life sciences sector. Continue reading for details on upcoming events, UK Parliament scrutiny of SVB Collapse, and more.

Revolutionising healthcare with data-driven innovation

Meet Danny Bosch, Associate Director of Business Development and Commercial at Imperial College Health Partners (ICHP). In his blog, Danny details how ICHP are working towards creating healthier populations, by unlocking the potential of innovation and supporting NHS and industry. 

Macomics and Ono Pharmaceutical partner to discover and develop macrophage-targeting antibody therapy for the treatment of cancer

Worldwide drug discovery collaboration agreement with Ono to develop new antibody drugs against a novel macrophage target of interest in immuno-oncology

Brainomix receives FDA clearance for its flagship stroke AI imaging software

The Oxford, UK headquartered company, long established as a market leader in Europe and a pioneer in the development of innovative stroke AI solutions, is now poised to take its transformative technology to US stroke centers

Unlocking the power of Virtual Reality to overcome anxiety and phobias

XR Therapeutics is a start-up company, spun out of Newcastle University, helping people to overcome their phobias or anxiety using Virtual Reality technology. We spoke with Penny Day, Head of Operations, about the role of virtual reality in mental health treatment, and how XR is making waves in this space.

CEO Update | 20 March 2023

The Budget last week had major wins for BIA members including changes to R&D tax credits rates for loss-making SMEs. Read our press release and Martin’s analysis blog. This is a major, major win for a BIA campaign and wouldn’t have happened without member engagement and perseverance. Many thanks to all who helped – this non dilutive government co-investment will make all the difference as you crowd in private sector investment.

More within